Antibody Drug Conjugates
Antibody Drug Conjugates
Antibody-drug conjugates (ADCs) are targeted cancer therapies that combine the precision of monoclonal antibodies (mAbs) with the potency of cytotoxic drugs. The mAb targets specific antigens on tumor or associated cells to target drug delivery to malignant tissue while sparing healthy cells. An ADC consists of three key components: a monoclonal antibody, a cytotoxic payload, and a chemical linker. The antibody functions as a homing device, recognizing and binding to target antigens on cancer cells. The payload is a highly potent therapeutic agent, often 100 to 1,000 times more cytotoxic than conventional chemotherapy drugs. The chemical linker connects the payload to the antibody and must be carefully engineered to remain stable during circulation while selectively releasing the drug at the intended target site. A critical ADC parameter is the drug-to-antibody ratio (DAR), which is defined as the average number of conjugated drugs on the antibody. This ratio is carefully designed and controlled to maximize efficacy while minimizing toxicity to healthy cells.
How Fluor Helps
Fluor brings decades of experience designing manufacturing facilities for biologics, including monoclonal antibodies (mAbs), small molecule payloads and linkers, and fill-finish operations. The company has also designed integrated facilities capable of supporting the full ADC manufacturing process, a capability that is uncommon given that ADC components are often produced at separate sites. In addition, Fluor's extensive expertise in high-potency manufacturing addresses one of the most critical and complex aspects of ADC production.
Process Features
ADCs are among the most complex and costly therapeutics to manufacture. In many cases, the antibody, linker, and payload are produced at different facilities, increasing supply chain complexity, coordination efforts, and overall manufacturing costs.
Production of the payload (small molecule), conjugation and purification, and fill-finish of the final product require capabilities for high-potency handling. This means specialized facilities with containment systems like gloveboxes, isolators, and controlled environments.
As a result, many developers rely on CDMOs to support ADC development and commercial production without significant in-house capital investment.
Challenges in ADC manufacturing include controlling impurities, toxicity, contamination, product loss, scalability, and maintaining regulatory compliance throughout the manufacturing process. Due to their unique complexity and evolving technology, regulatory requirements for ADCs have lagged and differ significantly across different countries and regions, which adds another layer of complexity for companies seeking global approval of their ADC products. Regulators are encouraging early communication and developing new guidance.
Beyond the inherent complexity of integrating biologics and small molecule manufacturing operations, ADC programs face a regulatory landscape that remains less harmonized than that of traditional biologics or small molecule Active Pharmaceutical Ingredients.
Facility Features
Manufacturing ADCs involves multiple process areas to manufacture the different components, as well as a conjugation suite. The biologics process to produce the mAbs is a well-established platform process involving upstream production in bioreactors, harvest, and downstream purification. The small molecule/API process involves more variability, as well as high-potency containment systems.
Fluor Projects
Confidential Client, CDMO Study
Location: North Carolina, USA
Scope: Feasibility and Conceptual Design
Fluor performed conceptual design for a 535,000-square-foot, greenfield, multi-technology CDMO facility for a confidential client, enabling integrated development through commercial manufacturing. The campus includes capabilities for small molecules, highly potent compounds, mammalian-expressed recombinant protein and monoclonal antibody biologics (43,000-square-foot), and antibody-drug conjugates, with dedicated drug substance production, fill-finish, and extensive process and analytical laboratories (159,000-square-foot). Fluor’s work established early cost, schedule, and design frameworks enabling flexible, scalable, and efficient end-to-end pharmaceutical production supporting diverse modalities.
Confidential Client, Project Launch Pad
Location: Washington, USA
Scope: Engineering and Long-Lead Equipment Procurement
Fluor supported a confidential client with initial feasibility/programming design, site selection support, master planning, conceptual and basic design for an entire 275,000-square-foot greenfield cGMP campus. The site comprised of utilizing single-use technology for drug substance and drug product manufacturing, utilities building, warehouse, and waste facilities. The facility includes dual 2,000L upstream suites with dedicated purification, as well as fill/finish with isolator technology for liquid and freeze-dried products.
Business Inquiries
Contact Fluor's sales team to learn how Fluor can help you with your business needs and what solutions Fluor offers in your industry. See the buttons below for questions on other topics.